(1S,3S,5S)-2-Azabicyclo-[3.1.0]hexane-3-carboxylic acid

Catalog No. :
ACGLZA435
CAS No. :
214193-13-2
Molecular Formula :
C6H9NO2
Molecular Weight :
127.14

IUPAC Name:(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid

(1S,3S,5S)-2-Azabicyclo-[3.1.0]hexane-3-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$262.00Login to see priceIn stockInquiry
250mg97%$410.00Login to see priceIn stockInquiry
500mg97%$706.00Login to see priceIn stockInquiry
1g97%$1003.00Login to see priceIn stockInquiry
5g97%$2967.00Login to see priceIn stockInquiry
10g97%$4984.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(1S,3S,5S)-2-Azabicyclo-[3.1.0]hexane-3-carboxylic acid
IUPAC Name(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid
MDL No.MFCD08691410
Molecular FormulaC6H9NO2
Molecular Weight127.14
SMILESO=C([C@H]1N[C@@]2([H])C[C@@]2([H])C1)O
InChI KeyXBEMWFUKTKDJKP-YUPRTTJUSA-N
Synonym(1S,3S,5S)-2-AZABICYCLO[3.1.0]HEXANE-3-CARBOXYLIC ACID;2-Azabicyclo[3.1.0]hexane-3-carboxylic acid, (1S,3S,5S)-;Saxagliptin Impurity 86;Nintedanib Impurity 161
CAS No.214193-13-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACGLZA435 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGLZA435 route product structure diagram
    ACGLZA435214193-13-2 In Stock
Inquiry

2. ACGLZA435 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGLZA435 route product structure diagram
    ACGLZA435214193-13-2 In Stock
Inquiry

Comments (0)